指南与共识银屑病与炎症性皮肤病

斑块状银屑病治疗中缓解的共识定义:国家银屑病基金会共识声明

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation.
指南 / 共识 · JAMA Dermatol · 2025-01-01

国家银屑病基金会通过多阶段德尔菲法(92名利益相关者参与)制定斑块状银屑病治疗中缓解的共识定义。最终定义为:在接受治疗期间,患者维持BSA为0%或IGA为0至少6个月。该标准化基准适用于研究和临床实践。

要点

  • 治疗中缓解定义为BSA 0%或IGA 0持续至少6个月。
  • 共识基于德尔菲法,纳入医生、患者、支付方等多方利益相关者。
  • 该定义旨在统一疗效评估和治療期望。

核心结论

  • 斑块状银屑病治疗中缓解定义为治疗期间维持BSA 0%或IGA 0至少6个月。

研究设计与样本

  • 国家银屑病基金会医学董事会和科学顾问委员会的缓解工作组发起多阶段德尔菲共识,包括预德尔菲访谈和调查以及德尔菲演练。
  • 共识过程涉及92名利益相关者,包括皮肤科医生、风湿科医生、研究人员、患者、支付方和生命科学专业人士。

主要发现

  • 预德尔菲访谈和调查中,患者强调治疗中缓解意味着在接受治疗时没有银屑病体征和症状。
  • 支付方表示定义缓解对长期治疗覆盖很重要。
  • 经过德尔菲演练和参与银屑病管理医生的讨论,达成上述缓解定义。

关键数值与推荐

  • 治疗中缓解:维持BSA为0%或IGA为0至少6个月(同时接受治疗)。

临床怎么用

  • 该标准化基准可用于研究和临床实践中评估治疗反应和统一治疗期望。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Defining on-treatment remission in plaque psoriasis is important for benchmarking patient responses to therapies. This also helps to facilitate shared understanding, align treatment expectations, and enable more effective psoriasis management. OBJECTIVE: To establish a consensus-based definition of on-treatment remission for plaque psoriasis through a multistage Delphi initiative. EVIDENCE REVIEW: The Remission Workgroup from the medical board and scientific advisory board of the National Psoriasis Foundation engaged various stakeholders, both US based and international, to participate in the consensus process. Following a working group meeting to determine the overall consensus approach, a systematic review of remission definitions in the current literature was performed. This review helped to inform the content of consensus materials. The consensus effort involved 2 stages: pre-Delphi interviews and surveys to inform the Delphi questions, followed by a Delphi exercise with physicians to define on-treatment remission for plaque psoriasis. Outcome measures considered included body surface area (BSA), Investigator Global Assessment (IGA), the product of the Physician Global Assessment and body surface area (PGA × BSA), and Psoriasis Area and Severity Index (PASI) score at various cutoff levels and time points. FINDINGS: The consensus process involved 92 stakeholders, including dermatologists, rheumatologists, researchers, patients, payers, and life sciences professionals. In the pre-Delphi interviews and surveys, patients emphasized that on-treatment remission meant the absence of psoriasis signs and symptoms while recieving therapy. Payers expressed that defining remission is important for long-term treatment coverage. Following the Delphi exercise and discussion with participating physicians specializing in psoriatic disease management, on-treatment remission in plaque psoriasis was defined as patients maintaining a BSA of 0% or IGA of 0 for at least 6 months while on treatment. CONCLUSIONS AND RELEVANCE: Through a Delphi consensus process, on-treatment remission for plaque psoriasis was defined as patients maintaining a BSA involvement of 0% or IGA of 0 for at least 6 months while on treatment. This clear and standardized benchmark is applicable to both research and practice settings.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Armstrong AW, Gondo GC, Merola JF, et al. Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation. JAMA Dermatol. 2025. PMID: 40531503. doi:10.1001/jamadermatol.2025.1625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。